Sirolimus-eluting Stents Versus Standard Stents In Patients With Stenosis In A Native Coronary Artery.
Jeffrey W. Moses, M. Bonilla León, Jeffrey J. Popma, Peter J. Fitzgerald, David R Holmes, Charles D O'shaughnessy, Ronald P. Caputo, Dean J Kereiakes, David O. Williams, Paul S. Teirstein, J. L. Jaeger, Richard E. Kuntz
Published 2003 · Medicine
Download PDFAnalyze on Scholarcy
BACKGROUND Preliminary reports of studies involving simple coronary lesions indicate that a sirolimus-eluting stent significantly reduces the risk of restenosis after percutaneous coronary revascularization. METHODS We conducted a randomized, double-blind trial comparing a sirolimus-eluting stent with a standard stent in 1058 patients at 53 centers in the United States who had a newly diagnosed lesion in a native coronary artery. The coronary disease in these patients was complex because of the frequent presence of diabetes (in 26 percent of patients), the high percentage of patients with longer lesions (mean, 14.4 mm), and small vessels (mean, 2.80 mm). The primary end point was failure of the target vessel (a composite of death from cardiac causes, myocardial infarction, and repeated percutaneous or surgical revascularization of the target vessel) within 270 days. RESULTS The rate of failure of the target vessel was reduced from 21.0 percent with a standard stent to 8.6 percent with a sirolimus-eluting stent (P<0.001)--a reduction that was driven largely by a decrease in the frequency of the need for revascularization of the target lesion (16.6 percent in the standard-stent group vs. 4.1 percent in the sirolimus-stent group, P<0.001). The frequency of neointimal hyperplasia within the stent was also decreased in the group that received sirolimus-eluting stents, as assessed by both angiography and intravascular ultrasonography. Subgroup analyses revealed a reduction in the rates of angiographic restenosis and target-lesion revascularization in all subgroups examined. CONCLUSIONS In this randomized clinical trial involving patients with complex coronary lesions, the use of a sirolimus-eluting stent had a consistent treatment effect, reducing the rates of restenosis and associated clinical events in all subgroups analyzed.
This paper references
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) Trial
David R Holmes (2002)
Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle.
Richard Gallo (1999)
Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study
Jose Eduardo M. Sousa (2001)
Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels.
Tatsurou Akiyama (1998)
A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery.
Francesco Versaci (1997)
A comparison of balloonexpandable – stent implantation with balloon angioplasty in patients with coronary artery disease
PW Serruys (1994)
Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model
Taizo Suzuki (2001)
A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.
David L Fischman (1994)
Vessel Size and Long-Term Outcome After Coronary Stent Placement
Intracoronary Stenting for Acute and Threatened Closure Complicating Percutaneous Transluminal Coronary Angioplasty
Gary S. Roubin (1992)
Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up
Jose Eduardo M. Sousa (2001)
Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up.
Benno J. Rensing (2001)
Improved clinical outcome after widespread use of coronary-artery stenting in Canada.
Janet M Rankin (1999)
Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis.
Ron Waksman (2000)
Predictors of angiographic restenosis after stenting : pooled analysis of 1197 patients with protocolmandated angiographic follow - up from 5 randomized stent trials
Ho KKL (1998)
The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation.
Andrea C. Abizaid (1998)
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.
M Morice (2002)
Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting
M. Bonilla León (2001)
Heparin infusion prior to stenting (HIPS) trial: final results of a prospective, randomized, controlled trial evaluating the effects of local vascular delivery on intimal hyperplasia.
Robert L. Wilensky (2000)
Bench to bedside: the development of rapamycin and its application to stent restenosis.
Steven O Marx (2001)
Paclitaxel Stent Coating Inhibits Neointimal Hyperplasia at 4 Weeks in a Porcine Model of Coronary Restenosis
Alan W. Heldman (2001)
Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis.
Gaston R. Dussaillant (1995)
Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome.
Roxana Mehran (1999)
Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement.
Shpend Elezi (1998)
Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months.
Douglas E Drachman (2000)
Management of restenosis within the Palmaz-Schatz coronary stent (the U.S. multicenter experience. The U.S. Palmaz-Schatz Stent Investigators.
Donald S. Baim (1993)
Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo.
Christian Herdeg (2000)
Stented segment length as an independent predictor of restenosis.
Yoshio Kobayashi (1999)
Three-year follow-up after implantation of metallic coronary-artery stents.
Toshio Kimura (1996)
Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty.
Ulrich Sigwart (1987)
Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial.
Michael J. B. Kutryk (2002)
de Feyter PJ (2000)
Mechanisms and results of balloon angioplasty for the treatment of in-stent restenosis.
Roxana Mehran (1996)
Influence of lesion length on restenosis after coronary stent placement.
Adnan Kastrati (1999)
This paper is referenced by
Coronary artery stents and non-cardiac surgery.
Georgina Howard-Alpe (2007)
Fratura de stent como causa de reestenose em stent farmacológico
Júlio César Machado Andréa (2008)
Stent Thrombosis in BMS and DES More issues than answers
Mitchell W. Krucoff ()
Cost comparison of four revascularisation procedures for the treatment of multivessel coronary artery disease
Xiaoyin Wang (2008)
Intravascular ultrasound in the drug-eluting stent era.
Gary S. Mintz (2006)
Raffaele Piccolo and Stephan Windecker With New Perspectives in the Era of New-Generation Drug-Eluting Stents Dual Antiplatelet Therapy in Percutaneous Coronary Intervention : A Tale of 2 Decades
Raffaele Piccolo (2016)
Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Katsuhisa Waseda (2009)
"Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents.
R. Joseph Applegate (2008)
Intravascular ultrasound assessment of neointima distribution and the length of stent that was free of intravascular ultrasound-detectable intimal hyperplasia in paclitaxel-eluting stents.
Gary S. Mintz (2005)
Resultados a largo plazo del stent farmacoactivo de zotarolimus según sus indicaciones de uso (aprobadas versus no aprobadas)
Paula Tejedor Viñuela (2014)
Angioplastie percutanee coronaire chez le patient diabetique. Partie 3: Nouvelles perspectives apportees par les stents enrobes.
Fabian Warzée (2004)
Nienaber Sirolimus-eluting stents for percutaneous coronary intervention in acute myocardial infarction Lesson from a case-controlled comparison of bare metal versus drug-eluting stents in thrombus-laden lesions
F. Weber (2004)
Evaluation of the suitability of a fluidized bed process for the coating of drug‐eluting stents
Monika Wentzlaff (2019)
Markers for silent myocardial ischemia in diabetes. Are they helpful?
Emmanuel Cosson (2005)
Influence of Elevated Temperature During Crimping on Results of Numerical Simulation of a Bioresorbable Stent Deployment Process
Jakub Bukala (2018)
Choice of Drug Eluting Stent : A Review
Jasmine George (2014)
Evaluating Treatment and Diagnostics in Cardiac Intervention
David Sparv (2018)
Trombose de stent farmacológico no "mundo-real": análise crítica do Registro DESIRE (Drug-Eluting Stent in the Real World)
Ricardo Alves da Costa (2008)
Will drug-eluting stents bankrupt the healthcare system?
Jason Ryan (2006)
Drug eluting coronary stent: in vitro evaluation of magnet resonance safety at 3 Tesla.
Frank G. Shellock (2005)
[Use of sirolimus-eluting stents in complex lesions: clinical and angiographic follow-up].
Juan M Ruiz-Nodar (2004)
COMBO dual-therapy stent: non-inferior to drug-eluting stents or stepping back to bare metal stents?
Kyohei Yamaji (2018)
Management of Acute Coronary Syndrome in Diabetes Mellitus
Jim M. John (2004)
2 Gender Differences in Coronary Artery Disease
Ryotaro Wake (2012)
Doo Yeon Kwon (2013)
Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating.
Jörg Hausleiter (2005)
Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents
Christoph Varenhorst (2018)
Characteristics of Coronary Lesions in Small Vessel Disease Treated with Elective Stenting in Patients with Type 2 Diabetes Mellitus
Alina Cordunean (2016)
Estrategias emergentes en cardiología intervencionista
Jiro Aoki (2005)
meta-Iodobenzylguanidine, an Inhibitor of Arginine-Dependent Mono(ADP-ribosyl)ation, Prevents Neointimal Hyperplasia
Lorraine Yau (2008)
Intervencionismo en el contexto del infarto de miocardio. Conceptos actuales
Eulogio García (2005)
Small Vessel Angioplasty
Lalita Nemani (2017)See more